
How Hong Kong stock exchange has simplified the IPO process
Professional services company EY reported that a majority of the 10 biggest IPOs on the Hong Kong stock exchange (HKEX) in 2024 were tech firms. On June 12, it shared that for the first half of 2025, A-share deals and proceeds increased 14 per cent year-on-year, with large IPOs propelling Hong Kong to world-leading IPO proceeds of US$14 billion.
Advertisement
'The surge is largely driven by substantial government investments in research and development, and support to enterprises spearheading the technology advancement and innovation ecosystem,' said Jack Chan, EY China chairman and Greater China regional managing partner. 'National strategic plans like Made in China 2025 have further enhanced market penetration, allowing Chinese enterprises to capture significant global market presence.'
Jack Chan, EY China chairman and Greater China regional managing partner. Photo: Handout
Made in China 2025 was unveiled 10 years ago and has largely succeeded in encouraging the development of technology and advanced manufacturing sectors.
Responding to this, HKEX and the Securities and Futures Commission (SFC) jointly launched the Technology Enterprises Channel (TECH) in May to help ease the listing process for specialist technology companies (under Chapter 18C of the listing rules) and biotech companies (18A). The channel will make dedicated teams available to help new firms get advice on listing rules, requirements and eligibility, especially as they apply to firms with products the markets may not be familiar with.
HKEX's Guide for New Listing Applicants repeatedly states that many examples were non-exhaustive, making assessments for eligibility a case-by-case exercise, particularly as many of the firms that would use TECH may be developing unfamiliar technologies. 'TECH is an important communication channel,' Chan said 'through which potential applicants can clarify their queries with HKEX in detail.'
Advertisement
Chan continued that other than this initial guidance, the IPO process remains the same. After enquiring via the channel, firms hope to have more clarity before meeting with the listing division and submitting pre-IPO enquiries. TECH helps these companies clarify the applicable listing rules before a new listing application is submitted.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


South China Morning Post
30 minutes ago
- South China Morning Post
Why some Chinese students are skipping elite universities amid job market fears
After underperforming in China's national college entrance exam in June, Lu Jie was accepted into a computer science and technology programme earlier this month at a lesser-known polytechnic university in central China's Hunan province. 'Good schools had too many applicants for this major, so I had to choose a lower-ranked one to pursue it,' Lu said. The results for the exam, better known as the gaokao , have been released over the past two weeks – marking a life-changing moment for students like Lu. Now more than ever, students are opting for majors with strong job prospects over prestigious universities. A focus on immediate employability and job security is eclipsing long-term aspirations and personal interests. Driving this trend is a growing oversupply of college graduates , intensifying competition in the job market amid a challenging economic climate. Computer science has long been a highly popular major, Lu said, but the rise of artificial intelligence (AI) – widely expected to create new job opportunities – has fuelled even greater demand over the past couple of years.


South China Morning Post
2 hours ago
- South China Morning Post
GSK signs US$12.5 billion licence deal with Hengrui as China rises in global pharmaceuticals
GlaxoSmithKline (GSK) will pay a Chinese company US$12.5 billion for exclusive global rights to develop a dozen drugs, in a landmark deal that underscores how China's research labs are snapping up market share in the global pharmaceutical and biomedical industries. Advertisement The deal would give GSK the rights to develop a drug for treating chronic obstructive pulmonary disease (COPD) called HRD-9821, as well as 11 of the preclinical programmes owned by Jiangsu Hengrui Pharmaceuticals. The global rights exclude mainland China, Taiwan, Hong Kong and Macau, according to a statement to the Hong Kong stock exchange on Monday. The deal is the latest in a string of transactions between multinational firms and Chinese drug developers, which have bolstered China's share of global licensing deal value to 28 per cent in 2024 from 1 per cent in 2019. Pfizer agreed in May to pay US$1.25 billion to Shenyang-based 3SBio for the exclusive right to develop the Chinese company's drug for treating solid tumours. China's pharmaceutical out-licensing value soared to almost US$66 billion in the first six months of 2025, more than the whole of last year, according to a July 14 report from China Post Securities. For multinational companies, the deals gave them exclusive products to expand their product portfolio and pipelines, while the Chinese developers saw them as opportunities to cash in on prior work and fund new projects. The corporate flag of GlaxoSmithKline (GSK) next to a Chinese national flag outside a GlaxoSmithKline office building in Shanghai on July 12, 2013. Photo: Reuters Hengrui, established in the Jiangsu provincial city of Lianyungang in 1997, would receive a US$500 million upfront payment and charge US$12 billion to GSK upon the achievement of development, regulatory approval and sales milestones. Advertisement 'The signing of the agreement will help expand the international market for HRS-9821 and multiple innovative medicines in various therapeutic areas, including oncology, respiratory, immunology and inflammation, providing high-quality treatment options for patients worldwide,' Hengrui said in a statement.


HKFP
2 hours ago
- HKFP
CK Hutchison eyes inviting Chinese ‘major strategic investor' to Panama ports deal
Hong Kong conglomerate CK Hutchison said Monday it was eyeing inviting a Chinese 'major strategic investor' to join a US-led consortium negotiating the sale of its global ports business outside China, including operations at the Panama Canal. The firm said in March it was offloading the firms — including operations in the vital Central American waterway — to a group led by asset manager BlackRock for US$19 billion in cash. The sale was seen as a political victory for US President Donald Trump, who had vowed to 'take back' the Panama Canal from alleged Chinese control, prompting Beijing's ire. China's market regulator said in March it was reviewing the deal. '(CK Hutchison) remains in discussions with members of the consortium with a view to inviting (a) major strategic investor from (China) to join as a significant member of the consortium,' the group said in a stock exchange filing. The firm added that changes to the consortium's membership and deal structure will be needed for the deal 'to be capable of being approved by all relevant authorities'. CK Hutchison announced in March it was offloading its global ports business outside China — including operations in the vital Central American waterway — to a group led by asset manager BlackRock for $19 billion in cash. The sale was seen as a political victory for US President Donald Trump, who had vowed to 'take back' the Panama Canal from alleged Chinese control, drawing Beijing's ire. China's market regulator said in March it was reviewing the deal. CK Hutchison said Monday that the 'period for exclusive negotiations' mentioned in the March announcement had expired, but that discussions will continue. It did not name the major Chinese investor. China's biggest shipping company Cosco was set to join the consortium and was requesting veto rights or equivalent powers, Bloomberg News reported. Bloomberg Intelligence analyst Denise Wong told the outlet that 'ongoing negotiations and the reported inclusion of Cosco Shipping in the consortium have likely eased concerns over Chinese regulatory hurdles, strengthening investor confidence in the deal's viability'. CK Hutchison said it 'intends to allow such time as is required for such discussions to achieve' a workable arrangement. It said it had stated on several occasions that it 'will not proceed with any transaction that does not have the approval of all relevant authorities'. Its Hong Kong-listed shares climbed nearly one percent Monday, while Cosco rose 0.5 percent. The consortium's original structure was designed to pass control of CK Hutchison's two Panama ports to BlackRock's Global Infrastructure Partners unit, while the remaining ports will go to Italian billionaire Gianluigi Aponte's Terminal Investment Limited. AFP has contacted Cosco for comment. The Panama Ports Company, a CK Hutchison subsidiary, has managed the port of Cristobal on the canal's Atlantic side and Balboa on the Pacific side since 1997, via a concession from the Panama government.